A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

NCT06158854 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin Light Chain (AL) Amyloidosis

Interventions

DRUG: ABBV-383 (Etentamig)

Sponsor

AbbVie